导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.06% | 1327/4773 |
| 近一周 | 1.53% | 2266/5517 |
| 近一月 | -8.91% | 5021/5427 |
| 近一季 | -20.50% | 4900/5241 |
| 近半年 | 1.42% | 1408/4939 |
| 近一年 | 9.66% | 1365/4404 |
| 近两年 | 122.20% | 441/2955 |
| 近三年 | 70.50% | 366/2255 |
| 成立以来 | 24.08% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.41% 1788/4961 |
36.79% 884/5312 |
- - |
- - |
| 2025 | 50.14% 467/4813 |
-1.80% 2780/3635 |
3.20% 1113/4076 |
49.81% 331/4524 |
-1.11% 2826/4813 |
| 2024 | 14.74% 1014/3463 |
-4.02% 1602/2808 |
-6.47% 1960/3014 |
29.60% 153/3129 |
-1.38% 1679/3463 |
| 2023 | -19.45% 1855/2656 |
1.97% 1474/2280 |
-7.10% 1778/2385 |
-9.63% 1862/2515 |
-5.91% 1553/2655 |
| 2022 | -29.40% 1599/2207 |
-19.81% 1495/1919 |
5.74% 836/2016 |
-18.52% 1718/2113 |
2.19% 1013/2208 |
| 2021 | 10.74% 420/1822 |
-7.31% 1060/1255 |
25.82% 83/1330 |
-6.77% 988/1466 |
1.85% 779/1822 |
| 2020 | - - |
- - |
- - |
- - |
10.53% 593/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 中银证券创业板ETF VS. 长安沪深300非周期A(740101) |